Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Participation in Leerink, NWR healthcare conferences

Thursday, March 13, 2025 1 min read
Key Takeaway: Radiopharm Theranostics is participating in the Leerink and NWR healthcare conferences. The company has recently received IND approval from the FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, the company has provided positive updates on its clinical programs, enhancing its profile in the biopharma sector.
Price reaction · baseline $5.57 (2025-03-12 close) · hit pre-market · 3 other RADX headline(s) in the window, move may be shared
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in notable healthcare conferences boosts visibility.
  • Positive clinical updates across multiple programs.
  • IND approval from the FDA indicates regulatory progress.

Full Press Release Details

• Announcements
• March 13, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• September 30, 2022
• Announcements
• April 15, 2024
• Announcements
• October 18, 2022
• Announcements
• October 22, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What conferences is Radiopharm participating in?

Radiopharm Theranostics is participating in the Leerink and NWR healthcare conferences.

What recent FDA approval did Radiopharm receive?

Radiopharm received IND approval from the FDA for a Phase I study targeting B7H3.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic product being studied by Radiopharm Theranostics.

What updates has Radiopharm provided?

Radiopharm has shared positive clinical updates across four of its programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase I study FDA approval healthcare conferences
Last updated: Mar 13, 2025